Hepatitis B Post-Exposure Prophylaxis Guidelines

Management Based on Vaccination Status and Source HBsAg Status

For exposure to HBsAg-positive source, the Centers for Disease Control and Prevention recommends administering HBIG (0.06 mL/kg body weight) as soon as possible (preferably within 24 hours) and beginning hepatitis B vaccine series simultaneously at a separate anatomic site 1, 2
For exposure to source with unknown HBsAg status, the Centers for Disease Control and Prevention recommends beginning hepatitis B vaccine series with first dose administered as soon as possible after exposure (preferably within 24 hours) 3, 4
The effectiveness of HBIG decreases significantly when administered >7 days after percutaneous exposure or >14 days after sexual exposure 3
Persons with documented immunity (anti-HBs ≥10 mIU/mL) do not require HBIG, additional vaccination, or testing after exposure, as per the Centers for Disease Control and Prevention guidelines 1, 5

Administration Guidelines

The Centers for Disease Control and Prevention recommends HBIG dose: 0.06 mL/kg body weight, administered intramuscularly 2
Hepatitis B vaccine should be administered simultaneously with HBIG at a separate anatomic site, according to the Centers for Disease Control and Prevention 2

Special Considerations

Postvaccination testing should be performed 1-2 months after completing the vaccine series for healthcare personnel and other high-risk groups, as recommended by the Centers for Disease Control and Prevention 6, 7
Testing after HBIG administration should be delayed until anti-HBs from HBIG is no longer detectable (4-6 months after administration), as per the Centers for Disease Control and Prevention guidelines 1, 5

Common Pitfalls to Avoid

Not completing the full hepatitis B vaccine series after exposure, as emphasized by the Centers for Disease Control and Prevention 1, 2
Assuming immunity without documented serologic testing after vaccination, a pitfall highlighted by the Centers for Disease Control and Prevention 8
Not recognizing that persons with documented immunity (anti-HBs ≥10 mIU/mL) do not require HBIG after exposure, as stated by the Centers for Disease Control and Prevention 1, 5

HBIG Administration Guidelines

Immediate Administration Recommendations

The Centers for Disease Control and Prevention (CDC) recommends administering HBIG immediately without waiting for blood test results when a healthcare worker with unknown anti-HBs status has high-risk exposure to an HBsAg-positive source, as the effectiveness of HBIG decreases markedly if delayed beyond 7 days after percutaneous exposure 9
For a healthcare provider with documented hepatitis B vaccination history but unknown anti-HBs titer exposed to an HBsAg-positive source, the CDC recommends administering HBIG (0.06 mL/kg) immediately, preferably within 24 hours of exposure, along with a hepatitis B vaccine booster dose at a separate anatomic site 9, 10

Follow-Up Testing Considerations

If HBIG is administered, the CDC recommends delaying postvaccination testing for anti-HBs until 4-6 months after HBIG administration to avoid detecting passively acquired antibodies from the immunoglobulin 9
The blood drawn at the time of exposure can still be tested later to determine baseline immunity status, and the CDC supports obtaining serum for anti-HBs testing immediately, but those with concentrations <10 mIU/mL should receive 1 dose of HBIG along with a booster dose of hepatitis B vaccine 9

Treatment Prioritization

The CDC prioritizes immediate prophylaxis over waiting for test results because giving HBIG to someone who is already immune causes no harm, and the risk of not treating someone who lacks immunity far outweighs the cost of treating someone who may already be protected 9
The American Academy of Family Physicians and the CDC framework explicitly address resource-limited settings by recommending immediate treatment based on exposure risk and vaccination history, not on awaiting confirmatory serology 9, 11

Post-Exposure Prophylaxis for Hepatitis B

Immediate Actions

The Centers for Disease Control and Prevention recommends testing the source patient for HBsAg to determine if the exposed individual has been exposed to Hepatitis B, within 24 hours of the needle prick incident 12, 13
If the source patient is HBsAg-positive, the exposed individual should receive HBIG (0.06 mL/kg) and a hepatitis B vaccine booster within 24 hours, especially if their anti-HBs status is unknown or if they have no documented immunity 14, 12
If the source patient's HBsAg status is unknown, the exposed individual should start the hepatitis B vaccine series immediately, preferably within 24 hours 12, 13, 15

Screening and Follow-up

The American Academy of Pediatrics recommends that individuals who have not been previously vaccinated should not undergo immediate HBsAg screening after exposure, but should instead start the hepatitis B vaccine series and undergo HBsAg and anti-HBs testing at 6 months to determine if they have been infected or have developed immunity from the vaccine 16, 14
If the individual has a history of vaccination but their immunity status is unknown, they should undergo anti-HBs testing immediately, and if the result is <10 mIU/mL and the source patient is HBsAg-positive, they should receive HBIG and a vaccine booster 14
The individual should undergo repeat anti-HBs testing 4-6 months after receiving HBIG to avoid detecting passive antibodies from the HBIG, and HBsAg testing at 6 months if they have not been confirmed to be anti-HBs positive 16, 14
The 6-month follow-up testing for hepatitis B is crucial, as the incubation period of the disease can be several months, and this timeframe allows for the detection of chronic infection and assessment of the immune response to the vaccine 16, 14

Hepatitis B Immune Globulin Prophylaxis for Needlestick Injuries

Dosing and Timing

Vaccination Coordination

Management According to Immunization Status

Vaccinated but Immune Status Unknown

Known Vaccine Non‑Responder

Administration Details

Follow‑Up Serologic Testing

Source Patient Assessment

Hepatitis B Post‑Exposure Prophylaxis after Needlestick Injury

1. Management when the Source is HBsAg‑Positive

Unvaccinated or incompletely vaccinated individuals should receive hepatitis B immune globulin (HBIG) 0.06 mL/kg intramuscularly and the first dose of hepatitis B vaccine at separate anatomic sites, preferably within 24 hours of exposure. The CDC recommends this rapid dual administration to maximize protection. 19
HBIG effectiveness declines sharply after 7 days post‑percutaneous exposure; therefore, administration as early as possible—ideally within 24 hours—is critical. [19][20]
If anti‑HBs ≥10 mIU/mL is documented (known immunity), no post‑exposure treatment is required. CDC guidance indicates that documented immunity provides complete protection. 20
When immunity status is unknown, give HBIG 0.06 mL/kg plus a single booster dose of hepatitis B vaccine at separate sites immediately, without awaiting serologic results. The American Family Physician advises prompt prophylaxis in this scenario. 21
For individuals with documented non‑response to a complete vaccine series (anti‑HBs <10 mIU/mL), administer HBIG 0.06 mL/kg immediately and a second HBIG dose one month later (total of two doses). No further vaccination is indicated. CDC recommendations outline this two‑dose regimen for confirmed non‑responders. [20][21]
Anti‑HBs testing should be performed 4–6 months after HBIG administration (or 1–2 months after completing the vaccine series if HBIG was not given) to assess true immune status and avoid detection of passively transferred antibodies. CDC specifies these timing windows. 20

2. Management when the Source’s HBsAg Status Is Unknown

Start the hepatitis B vaccine series immediately (first dose within 24 hours), regardless of the recipient’s vaccination history. CDC advises early vaccination when source status cannot be confirmed. [19][22]
HBIG is not indicated unless the source is later identified as high‑risk for HBV infection. CDC recommends reserving HBIG for confirmed high‑risk exposures. [19][22]
Previously vaccinated individuals require no additional treatment when the source’s HBsAg status is unknown. CDC guidance reflects that prior vaccination confers sufficient protection. [19][22]

3. Management when the Source Is HBsAg‑Negative

No HBIG or additional hepatitis B vaccination is needed, irrespective of the recipient’s prior vaccination status. The American Family Physician states that a negative source eliminates the need for post‑exposure prophylaxis. 21

4. HBIG Administration Details

Dose: 0.06 mL/kg body weight, administered intramuscularly (commonly in the deltoid).** Both CDC and American Family Physician specify this dosing. [19][21]
Separate Sites: HBIG and hepatitis B vaccine must be injected at different anatomic locations to ensure optimal immune response.** CDC emphasizes this requirement. 19

5. Vaccination Schedule and Serologic Follow‑Up

Standard vaccine series: 0, 1, and 6 months (three doses).** (Implicit in CDC recommendations.)
Protective immunity is defined as anti‑HBs ≥10 mIU/mL. CDC defines this threshold for adequate protection. [19][20]
Post‑vaccination anti‑HBs testing:
- If HBIG was not given → test 1–2 months after the final vaccine dose.
- If HBIG was given → test 4–6 months after the last HBIG dose.

All recommendations are based on CDC (MMWR Recommendations and Reports) and American Family Physician guidelines, with citation IDs provided for each fact.

Post‑Exposure Prophylaxis for Hepatitis B After Needlestick Injury

Source Assessment

Management decisions are based solely on the source’s HBsAg status (positive, negative, or unknown); quantitative HBV DNA viral load does not influence post‑exposure prophylaxis. 23

Immediate Wound Management

The needlestick site should be washed promptly with soap and water. 23
The injury (type, depth, presence of blood) and the source patient’s identity must be documented in detail. 23
The source patient should be tested for HBsAg immediately to confirm exposure risk. 23
If the source is confirmed HBsAg‑positive, prophylaxis should be initiated without waiting for any additional results. 23

Prophylaxis Administration

HBIG: Administer 0.06 mL/kg intramuscularly as soon as possible (ideally within 24 hours; maximal benefit if given within 7 days). 23
Vaccine: Give a hepatitis B vaccine dose at a separate anatomic site (e.g., opposite deltoid) at the same time as HBIG. 23
For healthcare workers who already have documented protective anti‑HBs (≥10 mIU/mL), no HBIG or additional vaccine dose is required. 23

Follow‑Up Testing

Anti‑HBs testing should be postponed until 4–6 months after HBIG administration to avoid detection of passively transferred antibodies. 23

Timing Considerations

HBIG effectiveness declines sharply when administered more than 7 days after a percutaneous exposure; therefore, administration within the first week is strongly recommended. 23

Immunity Considerations

Healthcare workers with documented immunity (anti‑HBs ≥ 10 mIU/mL) require no post‑exposure treatment, regardless of the exposure circumstance. 23

Timing and Efficacy of Hepatitis B Immunoglobulin (HBIG) After Exposure

General Recommendations

HBIG remains effective when given up to 7 days after percutaneous exposure and up to 14 days after sexual exposure; therefore administration beyond the traditional 24‑hour window is recommended when needed. 24
The optimal goal is to give HBIG within 24 hours of exposure for maximal protection, but this is a target rather than an absolute cutoff. 24
The protective effect of HBIG declines markedly after 7 days (percutaneous) or 14 days (sexual), at which point it may no longer provide meaningful prophylaxis. 24

Percutaneous (Needlestick) Exposures

Dose & Timing: Give 0.06 mL/kg intramuscularly as soon as possible; effectiveness is retained up to 7 days post‑exposure. 24
When identified >24 hours but ≤7 days: Administer HBIG immediately without waiting for serologic results. 24

Sexual Exposures

Timing Window: HBIG should be administered within 14 days of the last sexual contact with an HBsAg‑positive source. 24
When identified >24 hours but ≤14 days: Give HBIG promptly; it still confers protection within this interval. 24

Clinical Decision Algorithm

If exposure is >24 hours but ≤7 days (percutaneous) or ≤14 days (sexual):
- Immediately give HBIG (no delay). 24
- Start the hepatitis B vaccine series concurrently at a separate anatomical site.
If exposure exceeds 7 days (percutaneous) or 14 days (sexual):
- HBIG efficacy is markedly reduced and may not provide meaningful protection. 24
- Nevertheless, initiate the hepatitis B vaccine series immediately because active immunization remains beneficial. 24

Critical Pitfalls to Avoid

Do not withhold HBIG solely because more than 24 hours have passed; the 24‑hour recommendation is for optimal efficacy, not a contraindication. 24
Do not assume HBIG is ineffective at 48–72 hours after percutaneous exposure; protective activity persists through the first week. 24

All statements are based on the 2021 *MMWR Recommendations and Reports* guideline, reflecting the agency’s current best‑practice recommendations.

Post‑Exposure Prophylaxis for HBsAg‑Positive Sources

Immediate Management of Exposure

Administer hepatitis B immune globulin (HBIG) at 0.06 mL/kg intramuscularly and start or complete the hepatitis B vaccine series as soon as possible—ideally within 24 hours of exposure—unless the exposed individual has documented protective immunity (anti‑HBs ≥ 10 mIU/mL). CDC MMWR 2021; 2021 [25][26]
Confirm the source’s HBsAg‑positive status by laboratory testing immediately after exposure. CDC MMWR 2018 26
Record the exposure type (percutaneous, mucosal, sexual contact, or other blood/body‑fluid contact). CDC MMWR 2021 25

Management Based on Vaccination/Immunity Status

Unvaccinated or Incompletely Vaccinated Persons

Give HBIG 0.06 mL/kg IM immediately (effective up to 7 days after a percutaneous exposure) and administer the first vaccine dose at a separate anatomic site. CDC MMWR 2021; 2018 [25][26]
Complete the three‑dose vaccine schedule at 0, 1, and 6 months. CDC MMWR 2021; 2018 [25][26]
Perform anti‑HBs testing 4–6 months after HBIG administration (not at 1–2 months) to avoid detecting passively transferred antibodies. CDC MMWR 2011; 2018 [27][26]

Previously Vaccinated – Documented Immunity (anti‑HBs ≥ 10 mIU/mL)

No post‑exposure treatment (HBIG or vaccine booster) or testing is required; documented immunity provides complete protection regardless of time since vaccination. CDC MMWR 2021; 2011; 2018 [25][27]26

Previously Vaccinated – Immunity Status Unknown

Administer HBIG 0.06 mL/kg IM plus one hepatitis B vaccine booster dose at a separate site immediately, without awaiting serologic results. CDC MMWR 2021; 2018 [25][26]

Previously Vaccinated – Documented Non‑Responder (anti‑HBs < 10 mIU/mL after two full 3‑dose series)

Give HBIG 0.06 mL/kg IM immediately and a second HBIG dose one month later (total of two doses). CDC MMWR 2021; 2011; 2018 [25][27]26
Do not give additional vaccine doses; the maximum recommended total is six vaccine doses. CDC MMWR 2011 27
Counsel that the individual remains susceptible and will require HBIG for any future HBsAg‑positive exposures. CDC MMWR 2011 27

HBIG Dosing, Route, and Timing

Dose: 0.06 mL/kg body weight, administered intramuscularly (typically deltoid). CDC MMWR 2021; 2018 [25][26]
Administer HBIG and hepatitis B vaccine at separate anatomic sites (e.g., opposite arms) to ensure optimal immune response. CDC MMWR 2021; 2018 [25][26]
HBIG effectiveness declines markedly after 7 days for percutaneous exposures and after 14 days for sexual exposures; however, it remains protective up to 7 days (percutaneous) and should not be withheld if 48–72 hours have passed. CDC MMWR 2021; 2018 [25][26]

Serologic Testing and Definition of Immunity

After HBIG administration, test anti‑HBs 4–6 months later to avoid false‑positive results from passive antibodies. CDC MMWR 2011; 2018 [27][26]
If HBIG was not given, test anti‑HBs 1–2 months after completing the vaccine series. CDC MMWR 2011; 2018 [27][26]
Protective immunity is defined as anti‑HBs ≥ 10 mIU/mL. CDC MMWR 2011; 2018 [27][26]

Management When Vaccine Was Given Without Prior Testing

If anti‑HBs < 10 mIU/mL after the first complete series, administer a second complete 3‑dose series and retest 1–2 months after the third dose. CDC MMWR 2011 27
If anti‑HBs remains < 10 mIU/mL after six total vaccine doses, test for HBsAg and anti‑HBc to exclude chronic HBV infection. CDC MMWR 2011 27

Documentation and Pitfalls

Accept only written, dated records of vaccination and post‑vaccination serology as proof of immunity; verbal history is insufficient and should be treated as unvaccinated. CDC MMWR 2018 26
Do not delay HBIG or vaccine administration while awaiting serologic results; immediate prophylaxis based on vaccination history is recommended. (derived from cited recommendations)

Special Populations

Healthcare personnel should have documented hepatitis B vaccination and post‑vaccination serology on file before any anticipated exposure. CDC MMWR 2011 27

Exposure When Source HBsAg Status Is Unknown

Unvaccinated or incompletely vaccinated individuals: initiate the hepatitis B vaccine series immediately (first dose within 24 hours); do not give HBIG unless the source is later confirmed high‑risk. CDC MMWR 2021; 2018 [25][26]
Previously vaccinated persons with documented immunity: no treatment required. CDC MMWR 2021; 2018 [25][26]
Previously vaccinated persons without documented immunity: complete the vaccine series; HBIG is not indicated unless the source is later confirmed HBsAg‑positive. CDC MMWR 2021; 2018 [25][26]

Simultaneous Administration of Hepatitis B Vaccine and Hepatitis B Immune Globulin (HBIG)

Indications for Same‑Day Prophylaxis

The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends that, when indicated for post‑exposure prophylaxis or prevention of perinatal transmission, hepatitis B vaccine and HBIG be given simultaneously at separate anatomic sites (e.g., opposite limbs). This applies to both adult and infant populations. 28, 29
Post‑exposure prophylaxis – For an unvaccinated individual exposed to an HBsAg‑positive source, ACIP advises administration of HBIG (0.06 mL/kg) and the first dose of hepatitis B vaccine as soon as possible, preferably within 24 hours, at different injection sites. 28, 29
Prevention of perinatal transmission – Infants born to HBsAg‑positive mothers should receive HBIG (0.5 mL) and the hepatitis B vaccine within 12 hours of birth, injected at separate sites. 29
Healthcare‑worker exposures – When a healthcare worker with unknown hepatitis B immunity is exposed to HBsAg‑positive blood, ACIP recommends immediate administration of HBIG and a vaccine booster dose at different sites, without awaiting serologic testing. 28

Critical Administration Requirements

Separate anatomic sites are mandatory to ensure optimal immune response; the two products must never be mixed in the same syringe or injected into the same site. This non‑negotiable rule is emphasized in CDC guidance and reinforced by earlier MMWR recommendations (1994, 2002). 28, 29, 30, 31
Preparation – HBIG and hepatitis B vaccine must be prepared separately; co‑administration in a single syringe is prohibited. 30, 31

Timing Considerations

Effectiveness window – HBIG’s protective effect declines markedly after 7 days for percutaneous exposures and after 14 days for sexual exposures; therefore, immediate simultaneous administration is critical. 28
Optimal timing – The preferred window for prophylaxis is within 24 hours of exposure, but administration up to 7 days post‑exposure remains protective for needlestick injuries. 28

Practical Pitfalls to Avoid

Do not delay HBIG or vaccine while awaiting serologic results; immediate prophylaxis based on exposure history is the standard of care. 28
Never inject at the same site – Even though some animal studies suggest potential interference when given at the same site, CDC guidelines continue to require separate injection sites. 28
Never mix the products – Combining HBIG and vaccine in a single syringe is expressly prohibited by CDC recommendations. 30, 31

Post‑Exposure Prophylaxis for Hepatitis B after Needle‑Stick Injury

Assessment of Immunization Status

Individuals with no documented hepatitis B immunity (anti‑HBs < 10 mIU/mL) should receive both hepatitis B vaccine and hepatitis B immune globulin (HBIG) immediately after exposure. 32

Management for Unvaccinated or Incompletely Vaccinated Persons

Administer HBIG at 0.06 mL/kg intramuscularly and the first dose of hepatitis B vaccine at separate anatomical sites (e.g., opposite arms) as soon as possible, preferably within the first 24 hours after exposure. 32
HBIG efficacy declines sharply after 7 days but remains protective up to day 7; therefore, do not postpone administration even if 48–72 hours have elapsed. 32
Complete the hepatitis B vaccine series on schedule at 0, 1, and 6 months. 32
Test anti‑HBs 4–6 months after HBIG administration (not at 1–2 months) to avoid detection of passively transferred antibodies. 32

Management for Previously Vaccinated Persons with Unknown Immunity

Give a single booster dose of hepatitis B vaccine plus HBIG 0.06 mL/kg intramuscularly at separate sites immediately, without awaiting serologic results. 32
Perform anti‑HBs testing 4–6 months after the combined prophylaxis to determine the true immune status. 32

Management for Persons with Documented Immunity (anti‑HBs ≥ 10 mIU/mL)

No post‑exposure prophylaxis (neither HBIG nor additional vaccine) or serologic testing is required, regardless of the time elapsed since the last vaccination. 32
Documented immunity confers long‑term protection even if antibody levels decline over time. 32

Management for Documented Non‑Responders (anti‑HBs < 10 mIU/mL after two complete 3‑dose series)

Administer HBIG 0.06 mL/kg intramuscularly immediately and a second dose of HBIG one month later (total of two doses). 32
Do not give additional hepatitis B vaccine doses; the maximum recommended total vaccine doses remain six. 32
Counsel that the individual remains susceptible to hepatitis B and will require HBIG for any future exposure to HBsAg‑positive sources. 32

HBIG Administration Details

HBIG dose: 0.06 mL per kilogram of body weight, given intramuscularly (commonly in the deltoid muscle). 32
HBIG and hepatitis B vaccine must be injected at separate anatomical sites and must never be mixed in the same syringe. 32
The optimal prophylactic window is within the first 24 hours, but administration up to 7 days post‑exposure remains protective for needle‑stick injuries. 32